The Effect of Intermittent Oral Anticonvulsant Levetiracetam in Prevention of Recurrence of Fever and Convulsion in Children

Investigating the Effect of Intermittent Oral Anticonvulsant Levetiracetam in Prevention of Recurrence of Fever and Convulsion in Children: a clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N170

Enrollment

108

Registered

2021-06-21

Start date

2021-05-20

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal seizure. Convulsions of newborn

Interventions

Intervention 1: The intervention group will receive only one dose of levetiracetam 30-60 mg (orally), in case of recurrence of fever and seizures, will receive for 9 months. Intervention 2: The contro

Eligibility

Sex/Gender

All

Age

6 Months to 60 Months

Inclusion criteria

Inclusion criteria: Age between 6 to 60 months History of fever and seizures at least once

Exclusion criteria

Exclusion criteria: Patients with immunodeficiency Neurological disorder and abnormal neurological examination Seizures due to infection of the central nervous system and developmental disorder or progressive nervous disease

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: At the beginning of the study, once a month for 9 months. Method of measurement: By asking the child's parents and the number of hospital visits.;Convulsions. Timepoint: At the beginning of the study, once a month for 9 months. Method of measurement: By asking the child's parents and the number of hospital visits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Shabani

Kermanshah University of Medical Sciences

javadshabani@yahoo.com+98 83 3721 8204

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026